Sompraz%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp

# Sompraz hp (Pantoprazole) ## Overview Pantoprazole is a proton pump inhibitor (PPI) that decreases the amount of acid produced in the stomach. It is available in oral and intravenous formulations. ## Primary Indications * Gastroesophageal reflux disease (GERD) * Erosive esophagitis healing and maintenance * H. pylori eradication (in combination with antibiotics) * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome) ## Adult Dosing * **GERD and Erosive Esophagitis:** 40 mg orally once daily. For severe erosive esophagitis, the dose may be increased to 40 mg twice daily. Maintenance therapy can be 40 mg once daily, or lower doses may be used based on clinical response. * **H. pylori Eradication:** 40 mg orally twice daily for 7 to 14 days in combination with specific antibiotics (e.g., amoxicillin and clarithromycin). * **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally twice daily. Doses can be titrated up to 240 mg daily (divided into two doses). * **Intravenous:** 40 mg IV once daily. For patients who cannot take oral medication, the IV dose is generally equivalent to the oral dose. ## Pediatric Dosing Dosing in pediatric patients varies significantly by age and indication. Always consult specific pediatric guidelines. * **GERD (6 months to 16 years):** Oral: 15-30 mg once daily depending on weight. IV: 1-1.5 mg/kg/day once daily. * **Erosive Esophagitis (5 years to 16 years):** Oral: 40 mg once daily. ## Dose Adjustments No dose adjustment is generally required for renal impairment. Caution and potential dose reduction may be considered in severe hepatic impairment. ## Contraindications * Known hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and flatulence. Long-term PPI use may be associated with an increased risk of fractures (hip, wrist, spine), Clostridium difficile infection, and vitamin B12 deficiency. ## Key Drug Interactions * **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, iron salts, and cyanocobalamin. * **Methotrexate:** PPIs may increase methotrexate levels. * **CYP2C19 substrates:** Fluoxetine, fluvoxamine, and others; monitor for potential altered concentrations. ## Monitoring * Monitor for signs and symptoms of H. pylori infection if used for eradication. * Monitor for clinical response to therapy. * Long-term therapy may warrant monitoring for vitamin B12 deficiency and bone mineral density. ## Clinical Pearls * Administer oral pantoprazole at least 30 minutes before a meal. * Enteric-coated tablets should not be crushed or chewed. * IV infusion should be given over 15 minutes. * Long-term use should be re-evaluated periodically to assess the need for continued therapy. *** *This information is intended for healthcare professionals. Always consult the official prescribing information and current clinical guidelines for the most up-to-date and comprehensive details.*